Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

Dry eye revenue guidance increased to approximately $12 million, compared with the previous $9 million to $11 million range.

Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) reported third-quarter 2026 revenue of $24.9 million and raised its full-year revenue guidance. Revenue rose 25% year over year. Interventional Glaucoma revenue increased 7% to $21.0 million; Interventional Dry Eye revenue reached $3.9 million, versus $0.2 million a year earlier and $2.7 million in the second quarter. Net loss narrowed to $6.8 million, or $0.12 per share, from $8.2 million, or $0.16 per share.

The company now expects 2026 revenue of $92 million to $93 million, up from $88 million to $92 million, and maintained adjusted operating expense guidance of $92 million to $94 million. Quarterly gross margin was 85.9%, versus 86.4% a year earlier. Cash usage fell 74% to $2.4 million, leaving $77.4 million in cash and equivalents at September 30; debt principal remained $40.0 million. Sight Sciences also launched its OMNI Ultra Surgical System.

19 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 revenue guidance raised to $92 million–$93 million, representing 19%–20% growth, from $88 million–$92 million.
• Moderate pointThird-quarter revenue increased 25% year over year to $24.9 million.
• Moderate pointInterventional Dry Eye third-quarter revenue reached $3.9 million, versus $0.2 million year over year and $2.7 million sequentially.
• Moderate pointInterventional Dry Eye third-quarter gross margin rose to 79.0% from 37.8% a year earlier.
• Moderate pointThird-quarter cash usage decreased 74% to $2.4 million from $9.1 million a year earlier.
• Moderate pointNine-month revenue increased to $68.010 million from $56.978 million a year earlier.
• Moderate pointNine-month gross margin increased to 87.9% from 85.8% a year earlier.
• Moderate pointNine-month net loss narrowed to $24.236 million, or $0.44 per share, from $34.264 million, or $0.66.

11 minor points

• Minor pointInterventional Glaucoma third-quarter revenue rose 7% year over year to $21.0 million.
• Minor pointThird-quarter gross profit increased to $21.4 million from $17.2 million a year earlier.
• Minor pointInterventional Glaucoma third-quarter gross margin increased to 87.2% from 86.9% a year earlier.
• Minor pointThird-quarter net loss narrowed to $6.8 million, or $0.12 per share, from $8.2 million, or $0.16.
• Minor pointThird-quarter operating loss narrowed to $6.128 million from $7.905 million a year earlier.
• Minor pointThird-quarter research and development expenses decreased 19% to $2.7 million year over year.
• Minor point. Forward-looking: it has not happened yet and may not happen.2026 dry eye revenue guidance increased to approximately $12 million from $9 million–$11 million; 2025 revenue was $1.6 million.
• Minor point. Forward-looking: it has not happened yet and may not happen.2026 glaucoma revenue guidance calls for $80 million–$81 million, representing 6%–7% growth.
• Minor pointThird-quarter glaucoma active customers increased to 1,253 from 1,197 a year earlier.
• Minor pointThird-quarter dry eye active customers increased to 222 from 50 a year earlier.
• Minor pointThird-quarter dry eye lid treatment units sold increased to 4,581 from 271 a year earlier.

Negative

• Moderate pointThird-quarter selling, general and administrative expenses increased 14% to $24.8 million year over year.
• Moderate pointThird-quarter adjusted operating expenses increased 21% to $24.0 million year over year.
• Moderate pointNine-month results included a $5.393 million litigation success fee. 1% of market cap
• Minor pointThird-quarter gross margin declined to 85.9% from 86.4% a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.2026 adjusted operating expense guidance remains $92 million–$94 million, representing a 5%–7% increase over 2025.

3 minor points

• Minor pointCash and equivalents fell to $77.4 million at September 30, 2026, from $79.8 million at June 30.
• Minor pointThird-quarter investment income declined to $692,000 from $965,000 a year earlier.
• Minor pointCommon shares outstanding increased to 55,219,266 at September 30, 2026, from 53,493,711 at December 31, 2025.

News Explained

The revised 2026 outlook assigns approximately $12 million to dry eye, up from the previous $9 million to $11 million range.

At September 30, 2026, Sight Sciences reported 55,219,266 common shares issued and outstanding, versus 53,493,711 at December 31, 2025; for holders whose share counts did not change, the larger total means a smaller ownership percentage, absent offsetting changes.

Key Figures

Q3 revenue: $24.9 million; up 25% Interventional Glaucoma revenue: $21.0 million; up 7% Interventional Dry Eye revenue: $3.9 million versus $0.2 million +5 more

Q3 revenue

$24.9 million; up 25%

Third quarter 2026 versus third quarter 2025

Interventional Glaucoma revenue

$21.0 million; up 7%

Third quarter 2026 versus third quarter 2025

Interventional Dry Eye revenue

$3.9 million versus $0.2 million

Third quarter 2026 versus third quarter 2025

Cash usage

$2.4 million; down 74%

Third quarter 2026 versus third quarter 2025

FY2026 revenue guidance

$92 million to $93 million

Raised from prior guidance of $88 million to $92 million

FY2026 revenue growth guidance

19% to 20%

Year-over-year

Interventional Glaucoma revenue guidance

$80 million to $81 million

FY2026 guidance; growth of 6% to 7%

Adjusted operating expenses guidance

$92 million to $94 million

FY2026 guidance maintained

Previous Earnings Reports

2 past events · Latest: Aug 05

Same Type 2 events

1. Aug 05

   Quarterly earnings

   24h Move

   +27.8%

   Raised 2026 revenue guidance to $88–$92 million, the prior range cited in this report.

2. May 06

   Quarterly earnings

   24h Move

   +23.0%

   Raised 2026 revenue guidance to $83.0–$89.0 million before subsequent increases.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gaap, non-gaap financial measure, 510(k) cleared, ce marked, +2 more

6 terms

gaap financial

"“GAAP”, and is referred to as a “non-GAAP financial measure”"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

non-gaap financial measure financial

"is referred to as a “non-GAAP financial measure”"

A non-GAAP financial measure is a way companies present their financial results that excludes certain expenses or income to show how they believe their core business is performing. It matters because it can give a clearer picture of how the company is really doing, but it can also be used to make results look better than they actually are.

510(k) cleared regulatory

"System is 510(k) cleared in the United States"

A 510(k) clearance is the U.S. Food and Drug Administration’s permission to market a medical device after the manufacturer shows it is sufficiently similar to one already legally sold. Think of it as getting a green light for a new product because it behaves like an approved model; it allows sales in the U.S. faster than a full approval and reduces regulatory risk, which can materially affect a company’s revenue prospects and valuation.

ce marked regulatory

"The OMNI Surgical System is CE Marked"

CE marked indicates that a product meets European Union safety, health and environmental requirements and bears the CE symbol, acting like a safety stamp or passport that allows the product to be sold across the EU and European Economic Area. For investors, a CE mark matters because it reduces regulatory barriers and legal risk, can speed market access and revenue, and signals the company has cleared essential compliance steps for that product—affecting sales potential, costs and valuation.

meibomian gland dysfunction medical

"dry eye disease due to meibomian gland dysfunction (MGD)"

A chronic eye condition where the meibomian glands in the eyelids fail to produce or release the normal oily layer that prevents tears from evaporating, leading to dry, irritated eyes and inflammation. It matters to investors because its prevalence and chronic nature create ongoing demand for diagnostics, prescription drugs, medical devices, and clinic services, which affects markets, product development, regulatory reviews, and healthcare spending related to ocular surface disease.

ab interno canaloplasty medical

"expansion of its pioneering ab interno canaloplasty platform"

A minimally invasive eye surgery for glaucoma that restores the eye’s natural fluid outflow by opening and dilating Schlemm’s canal from inside the eye, typically using a tiny catheter and a tensioning suture or similar device. Think of it like threading and widening a clogged drainpipe from the inside to let fluid flow more freely; it matters to investors because adoption, device suppliers, procedure volumes and reimbursement affect companies in ophthalmic devices and surgical services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2026.

Recent Financial and Business Highlights

• Record revenue of $24.9 million in the third quarter of 2026, a 25% increase compared to $19.9 million in the third quarter of 2025.
  
  
• Interventional Glaucoma (IG) revenue of $21.0 million, a 7% increase compared to $19.7 million in the third quarter of 2025.
  
  
• Record Interventional Dry Eye (IDE) revenue of $3.9 million, a significant increase compared to $0.2 million in the third quarter of 2025, and a 45% increase compared to $2.7 million in the second quarter of 2026.
  
  
• Cash and cash equivalents totaled $77.4 million as of September 30, 2026. Cash usage was $2.4 million in the third quarter of 2026, down 74% compared to the same period in the prior year.
  
  
• Launched its OMNI® Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab interno canaloplasty platform, at the American Academy of Ophthalmology (AAO) annual meeting.
  
  

“We delivered another strong quarter with 25% total revenue growth, record IDE revenue, continued IG revenue growth, and a significant reduction in cash burn. These results demonstrate increasing adoption of our technologies, disciplined execution across our organization, and our growing impact on patients with glaucoma and dry eye disease,” said Paul Badawi, Co-Founder and CEO of Sight Sciences. “With IG strengthening our foundation and IDE rapidly developing into a meaningful growth driver, we are demonstrating the strength of our interventional eye care platform and the significant opportunity ahead. We remain focused on expanding the adoption of our technologies and advancing interventional eye care for the customers and patients we serve.”

Third Quarter 2026 Financial Results
Revenue for the third quarter of 2026 was $24.9 million, an increase of 25% compared to the same period in the prior year. IG revenue was $21.0 million, an increase of 7% compared to the same period in the prior year. IDE revenue was $3.9 million, compared to $0.2 million in the same period in the prior year.

Gross profit for the third quarter of 2026 was $21.4 million compared to $17.2 million in the same period in the prior year. Gross margin for the third quarter of 2026 was 86%, in-line with the prior year period. IG gross margin was 87%, in-line with the prior year period. IDE margin was 79%, up from 38% in the same period in the prior year.

Total operating expenses were $27.5 million in the third quarter of 2026, representing a 10% increase compared to $25.1 million in the same period in the prior year. Research and development expenses were $2.7 million in the third quarter of 2026 compared to $3.4 million in the same period in the prior year, representing a 19% decrease. Selling, general, and administrative expenses were $24.8 million in the third quarter of 2026, compared to $21.8 million in the same period in the prior year, representing a 14% increase. Adjusted operating expenses^1,2 were $24.0 million in the third quarter of 2026, a 21% increase compared to the same period in the prior year.

Net loss was $6.8 million, a 17% improvement from $8.2 million in the same period in the prior year. Net loss per share was $0.12, compared to $0.16 in the third quarter of 2025.

Cash and cash equivalents totaled $77.4 million and total debt was $40.0 million (excluding unamortized discount and debt issuance costs) as of September 30, 2026, compared to $79.8 million and $40.0 million, respectively, as of June 30, 2026. Cash used in the third quarter of 2026 totaled $2.4 million, a 74% decrease compared to $9.1 million in the third quarter of 2025.

2026 Financial Guidance
Sight Sciences raised its revenue guidance for full year 2026 to range from $92 million to $93 million, representing year-over-year growth of 19% to 20%, versus prior revenue guidance of $88 million to $92 million. This revenue guidance includes Interventional Glaucoma revenue of $80 million to $81 million, representing growth of 6% to 7%, and Interventional Dry Eye revenue of approximately $12 million, compared to the previous range of $9 million to $11 million and compared to $1.6 million in 2025.

The Company maintained its full year 2026 adjusted operating expenses^1,3 guidance to range from $92 million to $94 million, representing an increase of 5% to 7% compared to 2025.

_{¹ “Adjusted operating expenses” is a financial measure not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”, and is referred to as a “non-GAAP financial measure”). “Adjusted operating expenses” is calculated as operating expenses less stock-based compensation expense, depreciation and amortization, restructuring and organizational transition costs, and other one-time costs.
² A reconciliation of the non-GAAP financial measure to the most directly comparable GAAP financial measure has been provided in the table titled "GAAP to Non-GAAP Reconciliation" attached to this press release.
³ Consistent with Securities and Exchange Commission (“SEC”) regulations, the Company has not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the “unreasonable efforts” exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments that may be made to the Company’s GAAP financial measures in calculating the non-GAAP financial measures.}

Non-GAAP Financial Measures

Adjusted operating expenses, a non-GAAP financial measure, is presented in this press release to provide information that may assist investors in understanding the Company's financial and operating results. The Company believes this non-GAAP financial measure is an important performance indicator because it excludes items that are unrelated to, and may not be indicative of, the Company's core financial and operating results. This non-GAAP financial measure, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be an appropriate measure for comparing the performance of other companies relative to the Company. This non-GAAP financial measure is not intended to represent, and should not be considered to be a more meaningful measure than, or an alternative to, measures of operating performance as determined in accordance with GAAP. To the extent the Company utilizes such non-GAAP financial measure in the future, it expects to calculate it using a consistent method from period to period. A reconciliation of adjusted operating expenses to the most directly comparable GAAP financial measure has been provided in the table titled "Non-GAAP to GAAP Reconciliation" attached to this press release.

Conference Call
Sight Sciences' management team will host a conference call today, November 4, 2026, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free, minimally invasive glaucoma surgery technology indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.

Visit www.sightsciences.com for more information. 

Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories.

© 2026 Sight Sciences. All rights reserved.

Forward-Looking Statements
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release or during the earnings call that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, but are not limited to, statements concerning: the Company’s Q4 and full year 2026 financial guidance; the strength of our interventional eye care platform and the significant opportunity ahead; our goal to expand the adoption of our technologies and advancing interventional eye care for the customers and patients we serve; market acceptance of our products; our ability to achieve our business strategy and objectives; our ability to make interventional eye care the new standard of care; and our ability to create long-term value for our stockholders. These statements often include words such as "anticipate," "expect," “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition, including without limitation changes to reimbursement coverage or payment decisions or reimbursement rates for our products; pricing pressure or changes in market share resulting from the evolving competitive landscape; the impact of tariffs on our products and the medical device industry generally; and disruptions to or increased costs associated with our supply chain, including as a result of having a limited number of suppliers. Should our underlying assumptions prove incorrect, actual results may differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption “Risk Factors” in our filings with the SEC, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

Media contact:
pr@SightSciences.com    

SIGHT SCIENCES, INC. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share data)
		September 30,				December 31,
		2026				2025
Assets
Current assets:
Cash and cash equivalents		$	77,402			$	91,965
Accounts receivable, net of allowance for credit losses of $183 and $234 at September 30, 2026 and December 31, 2025, respectively			13,380				9,745
Inventory, net			6,502				7,767
Prepaid expenses and other current assets			4,186				3,257
Total current assets			101,470				112,734
Property and equipment, net			1,711				1,610
Operating lease right-of-use assets			1,077				438
Other noncurrent assets			690				518
Total assets		$	104,948			$	115,300
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	2,782			$	1,343
Accrued compensation			6,483				6,074
Accrued and other current liabilities			4,809				3,610
Short-term debt, net			6,063				—
Total current liabilities			20,137				11,027
Long-term debt, net			34,966				40,300
Other noncurrent liabilities			708				31
Total liabilities			55,811				51,358
Commitments and contingencies
Stockholders’ equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2026 and December 31, 2025			—				—
Common stock, par value $0.001 per share; 200,000,000 shares authorized; 55,219,266 and 53,493,711 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively			55				54
Additional paid-in-capital			458,041				448,611
Accumulated deficit			(408,959	)			(384,723	)
Total stockholders’ equity			49,137				63,942
Total liabilities and stockholders’ equity		$	104,948			$	115,300

SIGHT SCIENCES, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue		$	24,923			$	19,906			$	68,010			$	56,978
Cost of goods sold			3,503				2,709				8,237				8,100
Gross profit			21,420				17,197				59,773				48,878
Operating expenses:
Research and development			2,706				3,352				7,763				12,169
Selling, general and administrative			24,842				21,750				74,438				70,139
Total operating expenses			27,548				25,102				82,201				82,308
Loss from operations			(6,128	)			(7,905	)			(22,428	)			(33,430	)
Investment income			692				965				2,111				3,139
Interest expense			(1,312	)			(1,306	)			(3,869	)			(3,853	)
Other income (expense), net			(51	)			(2	)			1				(118	)
Loss before income taxes			(6,799	)			(8,248	)			(24,185	)			(34,262	)
Provision (benefit) for income taxes			11				(79	)			51				2
Net loss and comprehensive loss		$	(6,810	)		$	(8,169	)		$	(24,236	)		$	(34,264	)
Net loss per share attributable to common stockholders, basic and diluted		$	(0.12	)		$	(0.16	)		$	(0.44	)		$	(0.66	)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted			55,126,312				52,377,805				54,529,397				51,834,063

SIGHT SCIENCES, INC. Gross Margin Disaggregation (Unaudited) (in thousands)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue
Interventional Glaucoma		$	21,046			$	19,718			$	60,105			$	56,063
Interventional Dry Eye			3,877				188				7,905				915
Total revenue			24,923				19,906				68,010				56,978
Cost of goods sold
Interventional Glaucoma			2,688				2,592				6,634				7,662
Interventional Dry Eye			815				117				1,603				438
Total cost of goods sold			3,503				2,709				8,237				8,100
Gross profit
Interventional Glaucoma			18,358				17,126				53,471				48,401
Interventional Dry Eye			3,062				71				6,302				477
Total gross profit			21,420				17,197				59,773				48,878
Gross margin
Interventional Glaucoma			87.2	%			86.9	%			89.0	%			86.3	%
Interventional Dry Eye			79.0	%			37.8	%			79.7	%			52.1	%
Total gross margin			85.9	%			86.4	%			87.9	%			85.8	%

SIGHT SCIENCES, INC. GAAP to Non-GAAP Reconciliation (Unaudited) (in thousands)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Operating Expenses:
Total Operating Expenses		$	27,548			$	25,102			$	82,201			$	82,308
Less: Stock-based Compensation			(2,810	)			(2,382	)			(8,382	)			(10,245	)
Less: Depreciation and Amortization			(110	)			(105	)			(307	)			(379	)
Less: Restructuring and organizational transition costs			(637	)			(2,803	)			(637	)			(2,803	)
Less: Litigation Success Fee			—				—				(5,393	)			—
Adjusted Operating Expenses(1)			23,991				19,812				67,482				68,881

_{¹ Please see section titled "Non-GAAP Financial Measures" for additional information.}

SIGHT SCIENCES, INC. Supplemental Financial Measures (Unaudited)
		Three Months Ended September 30,
		2026				2025
Interventional Glaucoma active customers(1)			1,253				1,197
Interventional Dry Eye lid treatment units sold(2)			4,581				271
Interventional Dry Eye active customers(3)			222				50

_{¹ “Interventional Glaucoma active customers” means the number of customers who ordered the OMNI Surgical System or the SION Surgical Instrument during the three months ended September 30, 2026 and 2025.
² “Interventional Dry Eye lid treatment units sold” means the quantity of TearCare SmartLids® sold during the three months ended September 30, 2026 and 2025.
³ “Interventional Dry Eye active customers” means the number of customers who ordered lid treatment units during the three months ended September 30, 2026 and 2025.}

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Sight Sciences' updated 2026 revenue guidance?

Sight Sciences expects $92 million to $93 million in 2026 revenue, representing 19% to 20% year-over-year growth, versus its previous $88 million to $92 million range. The outlook includes glaucoma revenue of $80 million to $81 million and dry eye revenue of approximately $12 million.

How did Sight Sciences perform in the third quarter of 2026?

Sight Sciences reported $24.9 million in revenue, up 25% year over year, and a net loss of $6.8 million, or $0.12 per share. The year-earlier net loss was $8.2 million, or $0.16 per share. Quarterly cash usage decreased 74% to $2.4 million.

What does Sight Sciences exclude from adjusted operating expenses?

Sight Sciences calculates adjusted operating expenses by excluding stock-based compensation, depreciation and amortization, restructuring and organizational transition costs, and other one-time costs from operating expenses. This measure is not prepared under generally accepted accounting principles. Third-quarter adjusted operating expenses were $24.0 million, compared with $27.5 million in total operating expenses.

How does Sight Sciences define active glaucoma customers?

Active glaucoma customers are customers who ordered the OMNI Surgical System or SION Surgical Instrument during the quarter. Sight Sciences counted 1,253 such customers in the three months ended September 30, 2026, compared with 1,197 in the corresponding 2025 period.